Skip to main navigation Skip to search Skip to main content

The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines

  • Benjamin H. Mullish
  • , Mohammed Nabil Quraishi
  • , Jonathan P. Segal
  • , Victoria L. McCune
  • , Melissa Baxter
  • , Gemma L. Marsden
  • , David Moore
  • , Alaric Colville
  • , Neeraj Bhala
  • , Tariq H. Iqbal
  • , Christopher Settle
  • , Graziella Kontkowski
  • , Ailsa L. Hart
  • , Peter Hawkey
  • , Horace RT Williams
  • , Simon D. Goldenberg*
  • *Corresponding author for this work

    Research output: Contribution to journalShort surveypeer-review

    53 Citations (Scopus)
    Original languageEnglish
    Pages (from-to)S1-S31
    JournalJournal of Hospital Infection
    Volume100
    DOIs
    Publication statusPublished - Sept 2018

    Bibliographical note

    Funding Information:
    There was no external funding for this work. BHM is the recipient of a Medical Research Council (MRC) Clinical Research Training Fellowship (grant reference: MR/R000875/1). BHM and HRTW receive support from the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre (BRC) based at Imperial College Healthcare NHS Trust and Imperial College London.

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    Keywords

    • Clostridium difficile
    • faecal transplant
    • inflammatory bowel disease
    • microbiota

    Cite this